

**CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY**

NAME **Erick H. Turner, M.D.**

DATE **9/3/2018**

PRESENT POSITION AND ADDRESS

Academic Rank:

1. **Associate Professor**
2. **Associate Professor (Joint)**
3. **Senior Scholar**

Department/Division:

1. **Psychiatry**
2. **Pharmacology & Physiology**
3. **Center for Ethics in Health Care**

Professional Address:

3710 SW US Veterans Hospital Road, P3MHDC
Portland, OR 97239

II. EDUCATION

Undergraduate and Graduate

- 9/85 – 6/89 MD, Oregon Health Sciences University, Portland, OR
9/82 – 5/85 BS in Science, Portland State University, Portland OR
9/75 – 6/77 Swedish Language Courses, University of Stockholm, Sweden
9/71 – 5/75 BA in Spanish and Psychology, Duke University, Durham, NC

Postgraduate:

National Institute of Mental Health (NIMH): Staff Fellow, Clinical Psychobiology Branch, Bethesda, Maryland, 7/92 – 4/98 (first year, ending June 1993, served as 4th and final year of psychiatry residency)

University of California: Irvine Medical Center, Orange, CA, Psychiatry resident, 7/89-6/92 (3 years—credit for 4th year of residency received with 1st year at NIMH—see below)

Certification:

American Board of Psychiatry & Neurology

Initial certification April 30, 1996 - December 31, 2006

Recertified February 6, 2012 - 2022

Licenses:

Maryland	Active	Expires: September 30, 2019
DEA	Active	Expires: 11-30-2020

III. PROFESSIONAL EXPERIENCE

Academic:

Department of Psychiatry, 5/2001–present, Associate Professor (promoted from Asst. June 2013)
Department of Pharmacology & Physiology, 4/2001 - present – Joint Associate Professor
Center for Ethics in Health Care, OHSU – Senior Scholar, 7/2008 – present
NIMH Staff Fellow 1992-1998 (also listed above under Postgraduate Education)

Administrative:

1998 – 2001: Medical Officer (Clinical Reviewer), Psychotropics Team, Division of
Neuropharmacologic Drug Products (DNDP), Center for Drug Evaluation and Research
(CDER), Food and Drug Administration (FDA), Rockville, MD

Other:

2001 – Present: Staff Psychiatrist, Portland VAMC, Portland, OR
Private practice (solo) – psychopharmacology
Dates 9/94 –3/01 (closed practice upon move to Portland, OR)
5415 W. Cedar Lane, Suite 201-B
Bethesda, Maryland 20814
Contemporary Psychiatric Services (group practice)
5920 Hubbard Drive, Rockville, MD 20852
12/93 - 8/94 (left group practice to set up solo practice)
Outpatient and inpatient psychiatry as independent contractor
Inpatient covg at Charter Bhvrl Health Systems at Potomac Ridge, Rockville, MD
Hopkins Bayview Med Ctr; Highland Health Facility
Baltimore, Maryland
On-call weekend coverage for emergency room psychiatric evaluations, admissions, and
for psychiatric wards
One 24-hour shift per month
7/93 - 8/94
Clínica Nueva Esperanza
Spanish-speaking mental health clinic subsidized by county
Medication management; some psychotherapy (in Spanish)
431 S. Bristol Street, Santa Ana, California 92703
9/91 - 6/92 (left California for NIMH position)
Lakeview Medical Group
Medication management provided on-site to clients of "board-and-care" homes

Patient population: chronically mentally ill, developmentally disabled
928 Town & Country Office Park, Orange, California 92668
10/90 - 6/92

Past hospital affiliations

NIH Clinical Center, Bethesda, MD, 7/92 – 3/98

Suburban Hospital, Bethesda, MD, 8/94 – 9/99

Charter Behavioral Health Systems at Potomac Ridge (formerly Potomac Ridge
Treatment Center), Rockville, MD, 1/94 - 1999

Hopkins Bayview Medical Center (formerly Francis Scott Key Medical Center),
Baltimore, MD, 7/93 – approx. 1994

Highland Health Facility, Baltimore, MD, 7/93 – approx. 1994

IV. SCHOLARSHIP

Area(s) of Research/Scholarly Interest:

Current: Transparency in medical research, esp. reporting bias (verifying clinical trial results in published literature vs. FDA Drug Approval Packages), conflict of interest disclosure

Previous: Clinical trials issues, FDA matters, placebo (esp. scientific need for), drug development process, interferon-induced depression, use of 5-hydroxytryptophan (serotonin precursor) in treatment of depression, mood disorders, seasonal affective disorder (SAD), circadian rhythms.

Grants and Contracts:

Federal:

VA Cooperative Study (CSP590) of the use of lithium to prevent suicide in patients with a recent suicide attempt. Site PI for Portland VA Medical Center. Summer 2015 – present. FTE 15%.

Scientific Resource Center II to Support AHRQ Effective Health Care Program: *Reporting Bias in Systematic Reviews and Meta-analyses*; Agency for Healthcare Research and Quality, HHS 290 2012 00004; Co-Investigator (PI: Mark Helfand, MD, MPH, MS). FTE 25%. December 2013 through FY2017.

Standard Care Pathway of STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder); multicenter clinical trial sponsored by NIMH; site subinvestigator at Portland VA Medical Center, 1/02 – 2007; site PI Peter Hauser, M.D.; study PI Gary Sachs, M.D.; 40% effort.

Randomized Acute Depression Pathway of STEP-BD; phase 4 placebo-controlled clinical trial of bipolar depression; subinvestigator; Portland VA Medical Center, 10/02 – 2006; site PI Peter Hauser, M.D.; study PI Gary Sachs, M.D.; 10% effort.

(Previous intramural NIMH support listed below)

State and Local:

Oregon Medical Research Foundation, \$30,000, awarded fall 2003, 5-Hydroxytryptophan (5-HTP) Augmentation of SSRI Therapy in Patients with Interferon-Induced Depression; PI. (Study not approved by IRB due to concerns re purity of dietary supplement; funds returned)

Other Support:

Runner-up, Open Science Prize, US Partner in application; UK Partner = Ben Goldacre & team. Excerpt from our entry: “OpenTrialsFDA will increase access, discoverability and opportunities for re-use of a large volume of high quality information currently hidden in user-unfriendly Federal Drug Administration (FDA) drug approval packages.” Prize funders: Howard Hughes Medical Institute, and Wellcome Trust. Amount of award for

becoming finalist: \$80,000. Final winner decided February 2017.

<http://opentrials.net/2016/11/08/opentrialsfda-frequently-asked-questions/>

University of Groningen, March 19, 2012 – February 1, 2013; 12,000 Euros (~\$15,000), for mentoring junior researcher on project on publication bias in clinical trials on anxiety disorders; PI Peter de Jonge, PhD, professor of psychiatry at that university's; 5% effort. Stanley Medical Research Foundation, \$100,000, March 2008 – March 2010; 30% effort; study PI; Resulted in publication "Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database"

Pharmaceutical company support:

Seroquel Augmentation of Venlafaxine in Patients with Treatment-Resistant Depression: A Double-Blind Placebo-Controlled Trial; Principal Investigator for investigator-sponsored two-center trial; grant from AstraZeneca for \$210,000; February 2004 – August 2005; study (and site) PI, 30% effort.

A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripiprazole as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder; site PI for multicenter study sponsored by BristolMyers Squibb; 2005 – 2006; 20% effort.

Aripiprazole vs. placebo for bipolar depression; site PI for multicenter trial sponsored by Bristol-Myers Squibb; 2004 – 2006; 15% effort.

A Randomized Double-Blind Placebo-Controlled Trial of Atomoxetine versus Placebo in Patients Unresponsive or Incompletely Responsive to SSRI Therapy; site subinvestigator (site PI was Peter Hauser, MD), Portland VAMC, December 2003 – 2006; 10% effort.

Olanzapine vs. ziprasidone in the treatment of schizophrenia. Multicenter phase 4 trial sponsored by Eli Lilly Neuroscience. Subinvestigator (site PI was Peter Hauser, MD); Portland VA Medical Center; 8/2001 - 8/2002.

Intramural NIH support (during NIMH fellowship)

As PI (all approx. 50% effort)

A positron emission tomographic (PET) study of the acute effects of bright artificial light in patients with seasonal affective disorder and healthy volunteers. Subinvestigator. Study conducted at NIMH. 1996-97.

A double-blind placebo-controlled study of single-dose metergoline in depressed seasonal affective disorder patients. Principal Investigator (PI). Study conducted at National Institute of Mental Health (NIMH). 1994-95.

Single-case trial of bright artificial light in the treatment of seasonal hot flashes. Principal investigator. NIMH. 1992-93.

As co-investigator (all approx. 20% effort)

Tryptophan depletion vs catecholamine depletion vs sham depletion in patients with seasonal affective disorder in remission with light therapy. Subinvestigator. Study conducted at National Institute of Mental Health (NIMH). 1996-97.

A positron emission tomography (PET) study of the effect of m-CPP on brain metabolism in

SAD patients versus controls. Principal Investigator. Study conducted at NIMH. 1995-96.
 Open-label trial of extended bed rest and darkness as a mood stabilizer in a patient with rapid-cycling bipolar disorder. Subinvestigator. NIMH. 1995-96.
 Crossover treatment trial of light visor vs. light box treatment in patients with seasonal affective disorder. Subinvestigator. NIMH. 1995-96.
 Double-blind placebo-controlled clinical trial of exogenous melatonin administration and withdrawal in patients with rapid-cycling bipolar disorder. Subinvestigator. NIMH. 1994-95.
 Double-blind placebo-controlled single-dose study of ipsapirone in patients with seasonal affective disorder. Subinvestigator. NIMH. 1993-94.
 Double-blind placebo-controlled trial of leuprolide (Lupron®) with and without testosterone replacement. Subinvestigator. NIMH, 1994-96.
 Open-label trial of bright artificial light in bipolar depression. Subinvestigator. NIMH. 1993-94.
 Double-blind placebo-controlled trial of cyanocobalamin (vitamin B12) in the treatment of seasonal affective disorder. Subinvestigator. NIMH. 1992-93.

Publications/Creative Work:

Peer-reviewed journal articles (reverse chronological order):

1. Wayant C, **Turner E**, Meyer C, Sinnett P, Vassar M. Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials. *JAMA Oncol*. Published online August 30, 2018. doi:10.1001/jamaoncol.2018.3738
2. Andrea Cipriani, Toshi A Furukawa*, Georgia Salanti*, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H **Turner**, Julian P T Higgins, Matthias Egger, Nozomi Takeshima, Yu Hayasaka, Hissei Imai, Kiyomi Shinohara, Aran Tajika, John P A Ioannidis, John R Geddes. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet* Published Online First: February 2018. doi:10.1016/S0140-6736(17)32802-7
3. Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature. 2017;7:e012886. doi:10.1136/bmjopen-2016-012886
4. de Vries YA, Roest AM, Beijers L, **Turner EH**, de Jonge P. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety_ A meta-analysis. *Eur Neuropsychopharmacol* 2016;:1–8. doi:10.1016/j.euroneuro.2016.09.370
5. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, **Turner EH**, Chaimani A, Ogawa Y, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Sukanuma A, Watanabe N, Stockton S, Geddes JR, Cipriani A. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. *BMJ Open* 2016;6:e010919. doi:10.1136/bmjopen-2015-010919
6. Coronado-Montoya S, Levis AW, Kwakkenbos L, Steele RJ, **Turner EH**, Thombs BD.

Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions. *PLoS ONE* 2016;**11**:e0153220.

<http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0153220>

7. de Vries YA, de Jonge P, van den Heuvel E, et al. Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. *Br J Psychiatry* 2016;208:515–21. doi:10.1192/bjp.bp.115.173450
8. Driessen E, Hollon SD, Bockting CLH, Cuijpers P, **Turner** EH. Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials. *PLoS ONE* 2015;10:e0137864. doi:10.1371/journal.pone.0137864
9. Roest AM, de Jonge P, Williams CD, de Vries YA, Schoevers RA, **Turner** EH: Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. *JAMA Psychiatry* 2015, 72:500–510.
10. Cuijpers, P., **Turner**, E. H., Koole, S. L., van Dijke, A., & Smit, F. (2014a). What is the threshold for a clinically relevant effect? The case of major depressive disorders. *Depression and Anxiety*, 31(5), 374–378. doi:10.1002/da.22249
11. Cuijpers, P., **Turner**, E. H., Mohr, D. C., Hofmann, S. G., Andersson, G., Berking, M., & Coyne, J. (2014b). Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. *Psychological Medicine*, 44(4), 685–695. doi:10.1017/S0033291713000457
12. **Turner** EH (2013) How to access and process FDA drug approval packages for use in research. *BMJ* 2013;347:f5992
13. **Turner** EH (2013) Publication bias, with a focus on psychiatry: causes and solutions. *CNS Drugs* 27: 457–468. doi:10.1007/s40263-013-0067-9.
14. Roseman M, **Turner** EH, Lexchin J, Coyne JC, Bero LA, et al. (2012) Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 345: e5155.
15. **Turner** EH, Knoepflmacher D, Shapley L (2012) Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. *PLoS Med* 9: e1001189. Available: <http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001189>
16. Thombs BD, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, **Turner** EH, and Ziegelstein RC. Rethinking recommendations for screening for depression in primary care. *CMAJ*. March 6, 2012 184:413-418.
17. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, **Turner** EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *JAMA: The Journal of the American Medical Association* (2011) vol. 305 (10) pp. 1008-17
18. Moreno SG, Sutton AJ, **Turner** EH, Abrams KR, Cooper NJ, Palmer TM, Ades AE. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. *BMJ*. 2009 Aug 7;339:b2981.

doi: 10.1136/bmj.b2981.

19. **Turner EH**, Matthews A, Linardatos E, Tell RA, Rosenthal R. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. *N Engl J Med*. 2008 Jan;358(3):252-60.
20. **Turner EH**, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol Ther*. 2006 Mar;109(3):325-38. Epub 2005 Jul 14. Review.
21. **Turner EH**. A Taxpayer-Funded Clinical Trials Registry and Results Database. *PLoS Med*. 2004 Dec;1(3):e60.
22. **Turner EH**, Blackwell AD. 5-hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. *Medical Hypotheses*, Volume 65, Issue 1, 2005, Pages 138-144.
23. **Turner EH**, Schwartz P, Lowe C, et al. A Double-Blind Placebo-Controlled Study of Single-Dose Metergoline in Depressed Seasonal Affective Disorder Patients. *Journal of Clinical Psychopharmacology*. 2002 Apr;22(2):216-20.
24. Postolache TT, Wehr TA, Doty RL, Sher L, **Turner EH**, Bartko JJ, Rosenthal NE. Patients with seasonal affective disorder have lower odor detection thresholds than control subjects. *Arch Gen Psychiatry*. 2002 Dec;59(12):1119-22.
25. **Turner EH**, Leibenluft E, Albert P, Wehr T, Rosenthal N. Effect of season and light treatment upon hot flashes in a perimenopausal SAD patient. *Chronobiology International*. 1995;12:290-297.
26. Dobscha, SK, Winterbottom L, Hoffman WE, **Turner EH**, et. al: Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center. *Psychiatr Serv*. 2003 Feb;54(2):195-200.
27. Sher L, Matthews JR, **Turner EH**, Postolache TT, Katz KS, Rosenthal NE: Early response to light therapy partially predicts long-term antidepressant effects in patients with seasonal affective disorder. *J Psychiatry Neurosci* 2001; 26(4): 336-8.
28. Wehr TA, Duncan WC, Jr., Sher L, Aeschbach D, Schwartz PJ, **Turner EH**, Postolache TT, Rosenthal NE et al.: A circadian signal of change of season in patients with seasonal affective disorder. *Arch Gen Psychiatry* 2001; 58(12): 1108-14.
29. Schwartz PJ, Rosenthal NE, Kajimura N, Han L, **Turner EH**, Bender C, Wehr TA. Ultradian oscillations in cranial thermoregulation and electroencephalographic slow-wave activity during sleep are abnormal in humans with annual winter depression. *Brain Res*. 2000;866:152-67.
30. Schwartz PJ, **Turner EH**, Garcia-Borreguero D, et al. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. *Psychiatry Res*. 1999;86:9-28.
31. Postolache TT, Doty RL, Wehr TA, Jimma LA, Han L, **Turner EH**, et al. Monorhinal odor identification and depression scores in patients with seasonal affective disorder. *J Affect Disord*. 1999;56:27-35.

32. Neuhaus IM, Schwartz PJ, **Turner EH**, et al. Gender differences in glycosylated hemoglobin levels in seasonal affective disorder patients and controls. *Compr Psychiatry*. 1999; 40:234-7.
33. Wehr TA, **Turner EH**, Shimada JM, Lowe CH, Barker C, Leibenluft E. Treatment of rapidly cycling bipolar patient by using extended bed rest and darkness to stabilize the timing and duration of sleep. *Biol Psychiatry*. 1998;43:822-8.
34. Rosenthal NE, Mazzanti CM, Barnett RL, Hardin TA, **Turner EH**, Lam GK, Ozaki N, Goldman D. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. *Mol Psychiatry*. 1998;3:175-7.
35. Postolache TT, Hardin TA, Myers FS, **Turner EH**, Yi LY, Barnett RL, Matthews JR, Rosenthal NE. Greater improvement in summer than with light treatment in winter in patients with seasonal affective disorder. *Am J Psychiatry*. 1998;155:1614-6.
36. Neumeister A, **Turner EH**, Matthews JR, et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. *Arch Gen Psychiatry*. 1998;55:524-30.
37. Feldman-Naim S, Lowe CH, Myers FS, **Turner EH**, Weinstock LM, Leibenluft E. Validation of the hypomania interview guide-seasonal affective disorder (HIGH-SAD) version in patients with rapid cycling bipolar disorder. *Depress Anxiety*. 1998;8:166-8.
38. Schwartz PJ, Rosenthal NE, **Turner EH**, Drake CL, Liberty V, Wehr TA. Seasonal variation in core temperature regulation during sleep in patients with winter seasonal affective disorder. *Biol Psychiatry*. 1997;42:122-31.
39. Schwartz PJ, Loe JA, Bash CN, Bove K, **Turner EH**, Frank JA, Wehr TA, Rosenthal NE. Seasonality and pituitary volume. *Psychiatry Res*. 1997;74:151-7.
40. Leibenluft E, Schmidt PJ, **Turner EH**, et al. Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men. *J Clin Endocrinol Metab*. 1997;82:3203-7.
41. Leibenluft E, Feldman-Naim S, **Turner EH**, Wehr TA, Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder [see comments]. *J Clin Psychiatry*. 1997;58:383-8.
42. Feldman-Naim S, **Turner EH**, Leibenluft E. Diurnal variation in the direction of mood switches in patients with rapid-cycling bipolar disorder. *J Clin Psychiatry*. 1997;58:79-84.
43. Feldman-Naim S, Myers FS, Clark CH, **Turner EH**, Leibenluft E. Agreement between face-to-face and telephone-administered mood ratings in patients with rapid cycling bipolar disorder. *Psychiatry Res*. 1997;71:129-32.
44. Ozaki N, Rosenthal NE, Pesonen U, Lappalainen J, Feldman-Naim S, Schwartz PJ, **Turner EH**, Goldman D. Two naturally occurring amino acid substitutions of the 5-HT_{2A} receptor: similar prevalence in patients with seasonal affective disorder and controls. *Biol Psychiatry*. 1996;40:1267-72.
45. Leibenluft E, Feldman-Naim S, **Turner EH**, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. *Biol Psychiatry*. 1996;40:731-5.

46. Drake CL, Schwartz PJ, **Turner EH**, Rosenthal NE. Cognitive performance in seasonal affective disorder: pattern recognition and the Stroop task. *J Nerv Ment Dis.* 1996;184:56-9.
47. Wehr TA, Schwartz PJ, **Turner EH**, Feldman-Naim S, Drake CL, Rosenthal NE. Bimodal patterns of human melatonin secretion consistent with a two-oscillator model of regulation. *Neurosci Lett.* 1995;194:105-8.
48. Wehr TA, Giesen HA, Moul DE, **Turner EH**, Schwartz PJ. Suppression of men's responses to seasonal changes in day length by modern artificial lighting. *Am J Physiol.* 1995;269:R173-8.
49. Swedo SE, Pleeter JD, Richter DM, Hoffman CL, Allen AJ, Hamburger SD, **Turner EH**, et al. Rates of seasonal affective disorder in children and adolescents. *Am J Psychiatry.* 1995;152:1016-9.
50. Leibenluft E, **Turner EH**, Feldman-Naim S, Schwartz PJ, Wehr TA, Rosenthal NE. Light therapy in patients with rapid cycling bipolar disorder: preliminary results. *Psychopharmacol Bull.* 1995;31:705-10.
51. Ozaki N, Rosenthal NE, Mazzola P, Chiueh CC, Hardin T, Garcia-Borreguero D, Schwartz PJ, **Turner E**, et al. Platelet [3H]paroxetine binding, 5-HT-stimulated Ca²⁺ response, and 5-HT content in winter seasonal affective disorder. *Biol Psychiatry.* 1994;36:458-66.
52. Oren DA, Teicher MH, Schwartz PJ, Glod C, **Turner EH**, et al. A controlled trial of cyanocobalamin (vitamin B12) in the treatment of winter seasonal affective disorder. *J Affect Disord.* 1994;32:197-200.
53. Hoffman WF, Ballard L, **Turner EH**, Casey DE. Three-year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. *Biol Psychiatry.* 1991 Nov 1;30(9):913-26.

Non-peer-reviewed (reverse chronological):

Invited Articles

1. **Turner EH**, Rosenthal R. Efficacy of antidepressants. *Bmj.* Mar 8 2008;336(7643):516-517.
2. **Turner EH**, Tramèr MR, et al. Debate: It Can Be Unethical Not to Use Placebo. *Public Library of Science Medicine.* "Second" half of debate; both halves indexed together as: Stang A, Hense H, Jöckel K, Turner EH, Tramèr MR (2005) Is It Always Unethical to Use a Placebo in a Clinical Trial? *PLoS Med* 2(3): e72. Available at <http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020072>

Letters to the editor

1. de Vries YA, **Turner EH**, Roest AM. Retraction of biased journal articles. *BMJ* 2015;351:h5497. doi:10.1136/bmj.h5497
2. **Turner EH.** (2015) From the FDA, we still hear mostly thunderous silence. *351*:h3763.

doi:10.1136/bmj.h3763

3. **Turner EH** (2013) Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry: Causes and Solutions." *CNS Drugs*. doi:10.1007/s40263-013-0099-1.
4. **Turner EH** (2011) The effect of funding source on outcome reporting among drug trials. *Ann Intern Med* 154: 137; author reply 138.
5. **Turner EH** (2010) All the relevant data? *BMJ* 341: c6487.
6. Loftis JM, **Turner EH**. Novel treatment strategies for depression in patients with hepatitis C. *Psychosomatics* 2010;51:357-8.
7. **Turner E**, Moreno SG, Sutton AJ (2009) Ranking antidepressants. *Lancet* 373: 1760; author reply 1761-1762.
8. **Turner EH**, Moaleji NJ, Arnold BL. Closing a Loophole in the FDA Amendments Act. *Science*. Oct 3 2008; 322(5898):44-46.
9. **Turner EH**. Posting FDA new drug application reviews. *JAMA*. Aug 22 2007;298(8):863-864.
10. **Turner E**, Tramèr M (2005) Authors' Reply. *PLoS Med* 2(6): e187. Available at: <http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020187>
11. **Turner E**. Correction/clarification about FDA review documents. *PLoS Med*. 2005 Dec;2(12):e422; author reply e423. Epub 2005 Dec 27.
12. Oren DA, Schwartz PJ, **Turner EH**, Rosenthal NE, Wehr TA. Olfactory function in winter seasonal affective disorder [letter]. *Am J Psychiatry*. 1995;152:1531-2.
13. Oren DA, **Turner EH**, Wehr TA. Abnormal circadian rhythms of plasma melatonin and body temperature in the delayed sleep phase syndrome [letter; comment]. *J Neurol Neurosurg Psychiatry*. 1995;58:379.
14. Clark C, Schocket LS, **Turner EH**, Rosenthal NE. Light visor maintenance of light box response [letter]. *Am J Psychiatry*. 1997;154:1172.

Books

No books or book chapters have been authored. However, Google Books search of title of first-authored article in *NEJM* (2008) led to 2,020 hits as of September 2018

Review articles (also listed under peer-reviewed articles)

1. **Turner EH** (2013) Publication bias, with a focus on psychiatry: causes and solutions. *CNS Drugs* 27: 457–468. doi:10.1007/s40263-013-0067-9.
2. Thombs BD, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, **Turner EH**, and Ziegelstein RC. Rethinking recommendations for screening for depression in primary care. *CMAJ*. March 6, 2012 184:413-418.
3. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, **Turner EH**, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *JAMA: The Journal of the American Medical Association* (2011) vol. 305 (10) pp. 1008-17

4. Moreno SG, Sutton AJ, **Turner EH**, Abrams KR, Cooper NJ, Palmer TM, Ades AE. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. *BMJ*. 2009 Aug 7;339:b2981. doi: 10.1136/bmj.b2981.
5. **Turner EH**, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol Ther*. 2006 Mar;109(3):325-38. Epub 2005 Jul 14. Review. (also listed under header for peer-reviewed articles)

Abstracts (reverse chronological):

1st authored abstracts

1. **Turner EH**, Chan AW, Oren DA, Bedrick S, Eighth International Congress on Peer Review and Scientific Publication, Poster: Proportion of National Institutes of Health RO1-Funded Clinical Trials Registered in ClinicalTrials.gov. Presented Sept 12, 2017.
2. **Turner EH**, Alavi S, Cipriani C, Furukawa T, Ivlev I, McKenna R, Ogawa Y, Eighth International Congress on Peer Review and Scientific Publication (aka Peer Review Congress), Poster: An Update on Reporting Bias in the Antidepressant Literature: An FDA-Controlled Examination of Drug Efficacy. Presented Sept 11, 2017.
3. Peer Review Congress, Vancouver, BC, September 2009. Poster: Multiple Publication of Positive vs. Negative Trial Results in Review Articles: Influence on Apparent "Weight of the Evidence"
4. Turner EH, Matthews A, Linardatos E. Selective publication of antidepressant clinical trials. New Clinical Drug Evaluation Unit (NCDEU), 46th Annual Meeting, Poster II-78, Boca Raton, FL. June 14, 2006. (Early version of paper published in 2008, also given as invited talk at same conference in 2008.)
5. Society for Clinical Trials, Orlando, FL, May 22, 2006; Session IC: Trial Conduct and Reporting; talk title: "Documentation of Publication Bias in Industry-Sponsored Clinical Trials of Antidepressants". (Pre-submission version of study later published in *NEJM*.)
6. Turner EH, et. al. Motor Activity as a Measure of Severity of Mood Disorders, New Clinical Drug Evaluation Unit (NCDEU), Poster II-043, Boca Raton, FL, 6/2002.
7. Turner EH, Matthews J, Feldman-Naim S, et al. Effect of m-CPP on brain metabolism in SAD patients and controls. . *Light Treatment and Biological Rhythms*. Vancouver, British Columbia; 1997:8.
8. Turner EH, Schwartz P, Clark C, Myers F, Rosenthal N. Metergoline's effect on SAD symptoms. . *Light Treatment and Biological Rhythms*. Bethesda, MD; 1996:3.
9. Turner E, Leibenluft E, Wehr T, Rosenthal N. Seasonal hot flushes responsive to morning light therapy in a perimenopausal SAD patient. . *Light Treatment and Biological Rhythms*. San Diego, CA; 1993:49.
10. Turner EH, Buchsbaum M, Haier R. Thalamic structure and function in younger schizophrenics. Student Research Forum, Oregon Health Sciences University. Portland, OR; 1988.

11. Turner E, Hoffman W, Casey D. Neuroanatomical correlates of drug-induced parkinsonism in schizophrenics. Student Research Forum, Oregon Health Sciences University. Portland, OR; 1987.

Non-first-authored abstracts

12. Matthews J, **Turner E**, Postolache T, et al. Acute effects of light therapy on cerebral blood flow in SAD patients and matched controls. *Light Treatment and Biological Rhythms*. Vancouver, British Columbia; 1997:7.
13. Neumeister A, **Turner E**, Matthews J, et al. Reversal of antidepressant effects of light therapy by tryptophan and catecholamine depletion in SAD patients. *Light Treatment and Biological Rhythms*. Vancouver, British Columbia; 1997:6.
14. Leibenluft E, **Turner E**, Feldman-Naim S, Rosenthal N, Wehr T. Circadian rhythms and rapid cycling. American Psychiatric Association. New York; 1996:Talk #3E.
15. Clark C, Schocket L, **Turner E**, Ashman S, Rosenthal N. Efficacy of the light visor in maintaining antidepressant response in SAD patients. *Light Treatment and Biological Rhythms*. Bethesda, MD; 1996:19.
16. Neuhaus I, Schwartz P, **Turner E**, Feldman-Naim S, Matthews J, Rosenthal N. A comparison of winter glycosylated hemoglobin levels in SAD patients and controls. *Light Treatment and Biological Rhythms*. Bethesda, MD; 1996:31.
17. Feldman-Naim S, Leibenluft E, **Turner E**. Circadian variation in the direction of mood switches in patients with rapid cycling bipolar disorder. *Light Treatment and Biological Rhythms*. Bethesda, MD; 1996:6.
18. Garcia-Borreguero D, **Turner E**, Schwartz P, et al. Behavioral effects of the serotonergic 5-HT-1a receptor agonist ipsapirone in patients with seasonal affective disorder. *Light Treatment and Biological Rhythms*. Bethesda, MD; 1994:11.
19. Ozaki N, Rosenthal N, Garcia-Borreguero D, et al. Studies of platelet serotonergic systems in winter seasonal affective disorder. *Light Treatment and Biological Rhythms*. San Diego, CA; 1993:44.
20. Hoffman W, Ballard L, **Turner E**, Casey D. Three year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. *Biological Psychiatry*. 1991;30:913-926.
21. Hoffman W, Hansen T, **Turner E**, Casey D. Correlation of ventricular brain ratio with drug-induced parkinsonism and tardive dyskinesia in hospitalized schizophrenics. *Biological Psychiatry*. Chicago; 1987:267.
22. Hoffman W, Labs S, **Turner E**, Casey D. Organic correlates of drug-induced parkinsonism. American Psychiatric Association. Chicago; 1987:51.
23. Hoffman W, Labs S, **Turner E**, Casey D. Tardive Dyskinesia and drug-induced parkinsonism: relationship to cerebral ventricular enlargement. *Collegium Internationale Neuro-Psychopharmacologicum (CINP)*. San Juan, PR; 1986.

Invited Lectures, Conference Presentations or Professorships:

International (some items involve 2 or more talks at one location)

1. University of British Columbia (UBC), Education Day; 2 consecutive class presentations to UBC Psychiatry residency program (all residents divided into 2 groups), Vancouver, BC, Canada, November 9, 2017. Title: “Publication Bias Exaggerates Efficacy of Antidepressants...and Just About Everything Else”.
2. University of British Columbia (UBC) Therapeutics Initiative, “Journal Pub” presentation, Vancouver, BC, Canada, November 9, 2017. Title: “Publication Bias Exaggerates Efficacy of Antidepressants...and Just About Everything Else”
3. World Conference on Research Integrity 2017, Amsterdam, Netherlands. Oral Presentation: About half of RCTs funded by NIH R01 grants do not appear to be registered in ClinicalTrials.gov, presented May 29, 2017, **Turner** EH, Chan AW, Oren DA, Bedrick S
4. 2017 Award for Sustained Parasitism. Research Parasite Awards <http://researchparasite.com> Flown to Waimea, HI to receive award on Jan 4, 2017.
5. OpenTrialsFDA: Unlocking the Trove of Clinical Trial Data in Drugs@FDA. Prototype—1 of 6 finalists for Open Science Prize—presented at [BD2K Open Data Science Symposium](#), sponsored by NIH, December 1, 2016.
6. University Medical Center Groningen, the Netherlands, March 4, 2015. Invited lecture to Department of Psychiatry on reporting bias.
7. University of Oxford, UK, March 2, 2015. Invited lecture to Oxford Clinical Trials Research Unit on reporting bias.
8. PhD Defense Examiner, University of Copenhagen, February 27, 2015. PhD thesis of Jeppe Schroll: “Unpublished data, particularly in relation to harms, in clinical trials”.
9. VU University, Amsterdam, the Netherlands, Feb 24, 2015. Invited lecture to Department of Clinical Psychology on reporting bias (with emphasis on psychotropic drugs).
10. Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland, June 8, 2011, 2 invited talks—1 lecture + 1 roundtable discussion on topics of publication bias and transparency of drug regulatory agencies
11. McGill University, Montreal, Canada, 2 invited talks on publication bias and efficacy of antidepressants, 1 at Jewish General Hospital, 1 at Centre of Genomics and Policy, April 13, 2011
12. University of British Columbia, Vancouver, BC, Canada, 4 invited talks to different audiences regarding publication bias and efficacy of antidepressants, March 2-3, 2011
13. Danish University Antidepressant Group, Keynote address: The Earth is Flat, $d < 0.5$: The Silly Debate About Antidepressant Efficacy, November 5, 2010, Holckenhavn Castle, Nyborg, Denmark
14. Canadian Institutes of Health Research: Evidence-Based Perspectives on Detection and Clinical Care of Depression: Critique and Conversation. Montreal, Quebec, Canada. October

2009

15. Danish Society for Psychiatric Epidemiology, Copenhagen, Denmark. Annual Meeting, Nov 6, 2008, “Selective Publication of Antidepressant Trials—Influence on Apparent Efficacy.” Part of invited symposium: “Antidepressants: Are They Effective?”

National

1. Symposium: Transparency at the US Food and Drug Administration. January 16, 2018. Held at Pew Charitable Trusts, Washington, DC. Available at <https://www.jhsph.edu/departments/health-policy-and-management/blueprint-for-transparency-at-the-food-and-drug-administration/index.html>
2. OpenTrialsFDA: Unlocking the Trove of Clinical Trial Data in Drugs@FDA. Invited seminar given at Johns Hopkins Bloomberg School of Public Health, December 2, 2016.
3. FORCE16, Portland, OR, April 18, 2016, panelist in session “Data By the People, For the People.
4. Dartmouth University, Psychiatric Research Center (PRC), presentation: “How Publication Bias Distorts the Risk-Benefit Ratio of Drugs in Psychiatry and Medicine in General”, October 16, 2015.
5. Physicians for a National Healthcare Program (PNHP); webinar: “Peeking through the FDA’s window on drug efficacy”, May 11, 2015.
6. American Psychiatric Association 2013, San Francisco, CA; Part of symposium: "Antidepressants in MDD - The efficacy debate", Abstract #1371; ET talk title: "To Be or Not To Be (Effective)...That is NOT the Question".
7. University of Michigan Department of Psychiatry Grand Rounds, March 13, 2013. Topic: Publication bias and psychiatric drugs.
8. American Psychological Association, San Diego, California, August 2010, talk: " The Emperor's New Journal Articles on Antidepressant Efficacy (and on Research in General)"; part of symposium entitled "Eat Your Data Raw – Data-Based Medicine Versus Evidence-Based Medicine"
9. APA 2009 – part of a symposium presented at 2009 American Psychiatric Association conference, entitled, “Do we have any effective treatments for depression?”
10. Creighton University Medical Center Distinguished Lecturer Series, Omaha, NE, Sept 3, 2008, “Selective Publication of Antidepressant Trials: Are Drugs as Effective as ‘Advertised’ in Peer-Reviewed Medical Journals?”
11. New Clinical Drug Evaluation Unit (NCDEU), Phoenix, AZ, May 27, 2008, “Selective Publication of Antidepressant Trials”, part of Workshop 5, Part II: Dissemination of Clinical Trials Results: A Necessary Step Toward Personalized Treatment
12. Clinical Trial Registries and Results Databases, conference organized by Center for Business Intelligence (CBI): Arlington, VA, April 2006, “A ‘Lost Ark’ of Clinical Trial Results—Gathering Dust at the FDA”

13. Grand Rounds, Long Beach VA Medical Center, "From Discovery to Market: An Inside View of the FDA Drug Development Process", Jan 2004
14. NIMH Multicenter Clinical Trials: IND Exemptions. New Clinical Drug Evaluation Unit. Boca Raton, FL; 2000. (Talk given on behalf of FDA, invited by NIMH, meeting sponsors.)
15. Estrogen prescribing varies with season and latitude. American Psychiatric Association. New York; 1996: Symposium 12, Talk C.

Regional and Local

1. MIRECC Presents: Antidepressant Efficacy and Publication Bias. Wednesday, February 7th
2. Presentation to OCTRI (Oregon Clinical & Translational Research) Program Directors Meeting. Publication Bias Exaggerates Efficacy of Antidepressants...and Just About Everything Else. December 15, 2017.
3. Seminar @ SMMART (Serial Measurements of Molecular and Architectural Responses to Therapy) Treatments Program, Sept 26, 2017, OHSU Center for Spatial Systems Biomedicine (OCCSB). FDA reviews for addressing reporting bias and possible relevance to preclinical research.
4. Clinical Trials Transparency Workshop, July 25, 2017, OHSU DMICE, co-presented with representative of Sense About Science USA and AllTrials USA
5. Oregon Psychological Association (OPA). Keynote address at conference in Eugene, May 6, 2017
6. Oregon Psychiatric Physicians Association (OPPA), February 24, 2017, Portland, OR. Antidepressant Efficacy and Publication Bias: 2017 Update.
7. Spring Colloquium, OHSU Psychology Division, April 13, 2016. "Publication Bias: Psychological and Pharmacologic Treatments for Depression...and Beyond"
8. Oregon Psychiatric Physicians Association (OPPA), Feb 12, 2016, Portland, OR. Publication Bias: Psychological and Pharmacologic Treatments for Depression...and Beyond.
9. 2014 Oregon Society of Health-System Pharmacists (OSHP) Annual Seminar. Reporting bias and drugs: Is what you read the truth, the whole truth, and nothing but the truth? April 27, 2014.
10. 2012 OHSU Medical Scientist Training Program (MSTP; MD-PhD) Program Retreat, September 29, 2012, McMenemy's Edgefield, Troutdale, Oregon.
11. Portland Psychological Association, talk: The Earth is Flat, $d < 0.5$: The Silly Debate About Antidepressant Efficacy, Portland, Oregon, February 17, 2011
12. Pacific Northwest Chapter of the Medical Library Association Annual Meeting, talk: Selective Publication & Drug Efficacy: Don't Believe Everything You (Don't) Read; Portland, Oregon, October 11, 2010
13. Advance Practice Nurses Conference 2010, September 24, 2010. Talk: 'The Debate about Antidepressant Efficacy: Magic Bullets or Worthless Placebos?'; Portland VA Medical

Center auditorium.

14. AMSA (American Medical Students Association) Integrity Week, May 6, 2009, Talk title: 'Evidence B(i)ased Medicine: Caveat Emptor (Caveat Lector)
15. Bioethics Study Group presentation, March 2009. Transparency or Translucency? Seeing Through the Emperor's Clothes of Evidence B(i)ased Medicine.
16. Lewis & Clark Graduate School of Education and Counseling, Center for Continuing Studies, Annual Continuing Education for Mental Health Therapists, January 30, 2009. Talk title: "Selective Publication of Antidepressant Trials: Are These Drugs as Effective as 'Advertised' in the Peer-Reviewed Literature?"
17. Oregon Psychiatric Association, Ashland, OR, Sept 20, 2008, "Selective Publication of Antidepressant Trials: How Well Do These Drugs Really Work?"
18. Department of Medical Informatics & Clinical Epidemiology, DMICE Informatics Conference, OHSU, Thursday, May 22, 2008, "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy"
19. Drug Effectiveness Review Project, 2008 Spring Governance Meeting, Portland, OR, May 2, 2008, "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy"
20. 19th Annual Kinsman Conference, April 16, 2008, Workshop B-1: "Truth telling and suppressed drug research data." Also member of panel: "Panel: Relationship of organization to community"
21. Behavioral Neuroscience Department, OHSU, March 21, 2007: "What does *all* the evidence say about lamotrigine's efficacy for acute bipolar depression?"
22. Oregon Psychiatric Association, Lake Oswego, OR, March 2, 2007, Critical Interpretation of Clinical Trial Data.
23. Reed College, Portland, OR, November 28 and December 1, 2006; presentation to psychology students: "What does all the evidence say about lamotrigine's efficacy for acute bipolar depression?"
24. Conference: Rational Prescribing – A Preferred Alternative to Formularies, Salem Hospital, "Evidence-Based Prescribing for Bipolar Disorder", Oct 2003
25. Providence Hospital, Portland, OR, Medical Grand Rounds (video broadcast throughout Providence system in west coast states), "FDA Regulation of Drug Development", July 2002

V. SERVICE

Membership in Professional Societies:

Feb 2018-present: Member, Cochrane Collaboration

May 2008-present: List of Industry-Independent Experts (list compiled by Jeanne Lenzer and colleagues for other journalists)

1989 – 1998 American Psychiatric Association

1993 – 1998 Washington Psychiatric Society

1993 – 1998 Society on Light Treatment and Biological Rhythms

Editorial and Ad Hoc Review Activities:

Peer reviewer for journals

1. Archives of General Psychiatry
2. British Medical Journal (BMJ)
3. Cochrane Collaboration, Methodology Review Group
4. Drug Information Journal
5. JAMA
6. Journal of Clinical & Consulting Psychology
7. Lancet
8. New England Journal of Medicine
9. Oregon State Drug Review (newsletter)
10. Pharmacoepidemiology and Drug Safety
11. PLoS Clinical Trials
12. PLoS Medicine
13. PLoS ONE
14. Systematic Reviews
15. Therapeutics Letter (Therapeutics Initiative, Univ British Columbia)
16. Trends in Cognitive Sciences
17. Trials (a BioMedCentral journal)

Other editorial activity

Depression Grid editor, The Dartmouth Institute for Health Policy and Clinical Practice, 2016-present. <http://optiongrid.org/option-grids/grid-landing/92>

Depression Grid Advisory Board member, The Dartmouth Institute for Health Policy and Clinical Practice, 2015-present.

Academic editor, PLoS ONE, 5/2007 – present

Editorial board, Drug Information Journal, 5/2002 - 12/2004

Academic editor, PLoS Clinical Trials (folded into PLoS ONE), 9/2005 - 4/2007

Committees:

International/National

Cochrane Collaboration committee to develop a tool to assess “Risk of Bias due to Missing Results”. Flown to Bristol, UK for meeting April 24-25, 2017. Follow-up work continues.

March 27, 2018 FDA Psychotropic Drugs Advisory Committee (PDAC) Meeting on NDA 209229 for Lucemyra (lofexidine hydrochloride) tablets for the symptomatic treatment of opioid withdrawal. Silver Spring, Maryland.

November 1, 2017: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting Announcement on NDA 210136 for CAM 2038 (buprenorphine injectable) for treatment of opioid dependence

October 31, 2017: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting on NDA 209819 for RBP-6000 (buprenorphine injectable) for treatment of opioid dependence

Selection Committee for Research Parasite and Research Host Awards. Award cycles 2018-2019.

OpenTrials Advisory Group, 2015 – present. (Group headed up by Ben Goldacre, author/transparency activist based in UK.)

PLOS Data Guidelines Board, November 2016 – present.

Nordic Cochrane Centre, Advisory Board, 2010 – present

Structured Product Labeling Workgroup on electronic indexing, Health Level 7 (international nonprofit), 2012 – 2014

FDA Transparency Task Force, June 2009, testimony provided

Institute of Medicine – testimony to panel making recommendations to Congress regarding Comparative Effectiveness Research. March 2009.

Member of Mock FDA Advisory Committee. Clients: Somerset Pharmaceuticals and BristolMyers-Squibb. Purpose: To discuss question of whether or not dietary restrictions should be required for the 20 mg dose of Emsam (transdermal patch, selegiline (MAOI)). Mock meeting October 14, 2005 in preparation for actual meeting October 26, 2005.

Institutional

7/2004 – 12/2004 Placebo Taskforce, member, PVAMC

12/2003 - 12/2006 Institutional Review Board (IRB), Member IRB#2 Portland VAMC

2/2002 - 12/2004 Research and Development Committee, member, PVAMC

10/2001 – 10/2002 Antidepressant Cost Reduction Workgroup, member, PVAMC

7/1993 – 7/1994 Executive Secretary, Intramural Review Board (IRB), NIMH Intramural Program, Bethesda, MD

Departmental

2012 – 2013 QTc Workgroup, Mental Health Service, Portland VAMC

Community Service:

Lincoln High School, Portland; SPARK lecture (Science, Policy, and Research Knowledge),

February 8, 2006, Selective Publication of the Medical Literature.
Science Fair Judge West Sylvan Middle School, Portland, OR, 2005 - 2006, 2009
Science Fair Judge Ainsworth Elementary School, Portland, OR, 2003 – 2004

Clinical Responsibilities (since last promotion):

Staff Psychiatrist, Outpatient Clinic, Portland VA Medical Center, March 2001 – present. Annual performance report overall rating of outstanding in numerous fiscal years.

VI. TEACHING

Direct Teaching (most items refer to multiple teaching encounters)

University of British Columbia (UBC), Education Day; 2 consecutive class presentations to UBC Psychiatry residency program (all residents divided into 2 groups), Vancouver, BC, Canada, November 9, 2017. Title: “Publication Bias Exaggerates Efficacy of Antidepressants...and Just About Everything Else”. [also listed above under Invited Lectures]

Invited by and taught class for Bill Hersh, Chair of DMICE Dept of OHSU and course director of DMICE EBM class. Topic: Publication bias. Aug 29, 2017.

Treatment of Bipolar Disorder. Have taught on this topic to 2nd year psychiatry residents, as part of their course on Neuroscience directed by William Hoffman and Lucy Lloyd. Dates: 1/2018, 2/2017, 12/2015, 12/2012, 12/2011.

Evidence-Based Medicine Course for psychiatry residents. Fall 2007 to present. 15 face-to-face teaching hours per year plus prep time. Course director. Co-teachers: Dr. Sahana Misra and OHSU reference librarians.

OHSU Psychiatry Resident Journal Club (coordinated by Julie Anderson, MD), September 27, 2016. Supervised and presided over presentation given by resident on topic of publication bias and conflict of interest.

Human Investigations Program (HIP), OHSU – one lecture annually, every 1-2 years, starting in 2003, most recently July 27, 2016 then Aug 1, 2017.

OHSU/OSU Department of Pharmacy, March 10, 2017, class within course 2016 Internal Medicine Review for PharmD students.

OHSU/OSU Department of Pharmacy, May 6, 2016, class within course 2016 Internal Medicine Review for PharmD students.

OHSU Informatics and Ethics seminar course, course leader Melissa Haendel; one of three guest presenters; my part lasted approx. 1 hour of 2.5-hour class. May 20, 2015.

Physicians for a National Healthcare Program (PNHP), presentation on reporting bias and the use of FDA data; 30 minutes; May 11, 2015. (*Also listed above under invited talks.*)

Principles of Clinical Medicine (PCM): One of 3 panelists on conflict of interest in medicine. October 14, 2014.

Scientific Resource Center (SRC): Webinars given to Evidence-based Practice Centers (EPCs) in

the US:

- (1) July 21, 2014: Peer-Reviewed Literature: Caveat Lector. The Problem of Outcome Reporting Bias. Shared hour-long presentation with Kay Dickersin, PhD.
- (2) August 13, 2014: How to access and process FDA drug approval packages for use in research. Shared hour-long presentation with Daniel Hartung, PharmD.
- (3) January 28, 2015: Searching for Published and Unpublished Trial Data on FDA Website. Hour-long webinar presented to EPC librarians.

Clinical supervision (cumulative 2001-June 2012) of individual trainees: 13 OHSU psychiatry residents, 3 pharmacy residents, 2 Mood Disorders Fellows.

Group clinical supervision of 3 psychiatry residents in Portland VA outpatient mental health clinic, July 2012 – December 2013.

OHSU 3rd MS-3 Didactics. Mood Disorders: October 2001 to December 2011. Bipolar Disorder: January 2012 to present.

FDA Regulation of Drug Development: 1st year medical students, OHSU, Pharmacology core curriculum, spring 2002-2008. Varied from 1 to 2 (consecutive) hours annually.

How the FDA Communicates with Physicians: 1st year medical students, OHSU, Pharmacology core curriculum, spring 2009-2014.

Neuroscience and Behavior Course, OHSU second year med students – three 1-hr seminars annually from spring 2004-2010 covering schizophrenia, mood disorders, and anxiety disorders

MIRECC (Mental Illness Research, Educational, and Clinical Center) 2/03.

OHSU Family Practice Residents, May 2009, Talk title: "Selective Publication of Antidepressant Trials: How Well Do These Drugs Really Work?"

Tips on Using That Rodney Dangerfield of Medical Books, The PDR, Grand Rounds, OHSU, 6/04

Statistical vs. Clinical Significance in Clinical Drug Trials: The Tyranny of the P Value in Deciding Whether and How Well our Drugs Really Work, Journal Club, given to Portland VA Mental Health Division, 6/03

An Amateur's Guide to Medline Searching, Journal Club, given to Portland VA Mental Health Division 9/03

Designing, Conducting, and Analyzing a Clinical Drug Trial: Student Research Presentation; Mentored small group of OHSU 1st year medical students as part of pharmacology curriculum ~10 one-hour sessions, 2/03– 4/03

Pharmacokinetics small group, 1st year medical students, 2-hr small group workshop, spring term 2003 to present (except 2010)

Pharmacology small group, Salicylate and acetaminophen overdose, 2-hour small group, spring 2003 – 2005

A patient with bipolar disorder and pathological gambling, Clinical Case Conference, given to Portland VA Mental Health Division, 12/02

Treatment of a rapid cycling bipolar patient using extended bed rest and darkness to stabilize the timing and duration of sleep, Clinical Case Conference, presented to PVAMC Mental Health Division, 10/01.

Seasonal Affective Disorder, 1-hr talk to nurse practitioners at Portland VA, December 2001

Seasonal Affective Disorder, Open Mood Disorders Forum, PVAMC Auditorium (lay audience, veterans + non-veterans)

Online CME Courses Taught

Psychopharmacology Institute: How to Read Papers in Psychiatry, Parts 1&2

<https://psychopharmacologyinstitute.com/education/premium-membership/>

Interview recorded May 1, 2015, published online July 2015.

Foundation for Excellence in Mental Health. "Unraveling the Bundles of Research Bias: Is What You Read the Truth, the Whole Truth and Nothing But the Truth?" Presented/generated on June 26, 2015. Available at: <http://madinamericacontinuinged.org/courses/unraveling-the-bundles-of-research-bias-is-what-you-read-the-truth-the-whole-truth-and-nothing-but-the-truth/>

Curriculum Development

Evidence-Based Medicine Course for psychiatry residents. Course director fall 2012 going forward. Previously co-director with Sahana Misra MD (2007 to spring 2012).

Developed class for veterans with mental health problems, "Medications for Mental Health". Taught class together with pharmacists, September 2004 to December 2005. 15-class series, 3 classes per blocks x 4 blocks (depression, bipolar disorder, schizophrenia, anxiety disorders & insomnia). Course ended due to difficulty sustaining recruitment of veterans.

Mentoring and Advising

Mentored early career Dutch psychologist (PhD) on project on publication bias with clinical trials of anti-anxiety medications. To be published in JAMA Psychiatry 2015.

Mentored two medical students (Lee Shapley and Daniel Knoepflmacher) during project on selective publication of antipsychotic trials, resulting in their co-authorship of article in peer-reviewed journal. Two to six hours per week spring 2009 through September 2009, followed by less frequent ad hoc contact.

Mentored medical student (Travis Redd) on project on selective publication of clinical trials of antihypertensive medications. Eight hours per week x 3 months, summer 2011.

Honors and Awards for Education

Regional/National

Distinguished Lecturer, Creighton University Medical Ctr, Omaha, NE, September 3, 2008